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CASE REPORT
Pulmonary veno-occlusive disease
misdiagnosed as idiopathic pulmonary
arterial hypertension
M. Palazzini and A. Manes
ABSTRACT: A 27-yr-old female with a 6-month diagnosis of idiopathic pulmonary arterial
hypertension (PAH) confirmed elsewhere was referred to our centre with worsening dyspnoea.
On examination, the patient had low systemic oxygen saturation despite high oxygen flow and
reduced exercise capacity. Haemodynamics were indicative of severe pre-capillary PAH. High-
resolution computed tomography revealed diffuse ground-glass opacity with thickening
interlobular septa, and haemosiderin-laden macrophages were identified by bronchoalveolar
lavage. Based on clinical and diagnostic findings, the patient was re-diagnosed with pulmonary
veno-occlusive disease (PVOD).
Treatment with high-dose diuretics and the endothelin-receptor antagonist bosentan improved
the patient’s exercise capacity, haemodynamics and quality of life. However, 1 yr later there was a
progressive, slow deterioration in the patient’s functional capacity and oxygen saturation, and
inhaled prostanoid and oxygen therapy were initiated. Despite some subjective improvements,
the patient’s haemodynamics and oxygen saturation continued to decline and she underwent lung
transplantation.
This case emphasises that PVOD is an under-recognised and often misdiagnosed form of
pulmonary hypertension. Therefore, accurate diagnosis of PVOD requires comprehensive clinical
and diagnostic work-up. While lung transplantation remains the treatment of choice for patients
with PVOD, targeted therapies for PAH in addition to high doses of diuretics merit evaluation.
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A
27-yr-old female was referred to the
Pulmonary Vascular Diseases Centre of
Bologna (Bologna, Italy) with a diagnosis
of idiopathic pulmonary arterial hypertension
(PAH) and a history of progressive dyspnoea
during exercise since the age of 26 yrs. In August
2005, while overseas, she had been admitted to
hospital for worsening dyspnoea. At this time she
was in New York Heart Association functional
class III and sarcoidosis was suspected. A
transbronchial biopsy was performed but the
sample was not sufficient for diagnosis. In
September 2005, she was referred to a respiratory
medicine department where sarcoidosis was
excluded and idiopathic PAH was diagnosed.
Diagnosis was confirmed 1 month later following
referral to an expert pulmonary hypertension
centre and treatment with high-dose sildenafil
was initiated (80 mg t.i.d.). However, after
1 month of treatment, the patient exhibited
worsening dyspnoea and was referred to our
centre (Pulmonary Hypertension Unit, Institute
of Cardiology, University of Bologna, Bologna) in
February 2006.
On examination, the patient had right heart failure,
low systemic oxygen saturation despite high
oxygen flow (88% on 6 L?min-1 oxygen flow by
nasal prongs), and reduced exercise capacity (6-
min walk distance (6MWD) 200 m). ECG showed
right ventricular hypertrophy with ventricular
strain pattern. Her chest radiograph showed
cardiomegaly, enlargement of the proximal pul-
monary artery and diffuse interstitial oedema with
basal Kerley B lines. Echocardiography confirmed
dilatation of the right heart chambers and abnorm-
alities in the shape and function of interventri-
cular septum. Perfusion lung scans identified
diffuse ‘‘patchy-like’’ sub-segmental hyperperfu-
sion defects.
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Right heart catheterisation (RHC) confirmed severe pre-capil-
lary pulmonary hypertension with a reduced cardiac index and
reduced systemic and mixed venous oxygen saturation
(table 1). Pulmonary wedge pressure was normal. Contrast
enhanced computed tomography of the chest excluded chronic
thromboembolic pulmonary disease, and high-resolution com-
puted tomography identified diffuse ground-glass opacities
with thickening interlobular septa (fig. 1). Bronchoalveolar
lavage identified haemosiderin-laden macrophages. Based on
these findings a diagnosis of pulmonary veno-occlusive disease
(PVOD) was hypothesised. Sildenafil was withdrawn and
treatment with high-dose diuretics (oral furosemide 125 mg
b.i.d.) and cautious use of the endothelin-receptor antagonist
bosentan (initial dose 62.5 mg t.i.d., up-titrated to 125 mg t.i.d.)
was initiated. Lung transplantation was considered.
After 4 months of treatment an improvement in the patient’s
exercise capacity (6MWD 500 m) and quality of life were
observed, and supplemental oxygen was withdrawn. RHC
showed a reduction in mean pulmonary arterial pressure, an
increase in cardiac index and an improvement in systemic and
mixed venous oxygen saturation (table 1). However, 1 yr later
there was a progressive, slow deterioration in the patient’s
functional capacity and oxygen saturation, and inhaled
iloprost (2.5 mg six times daily) was added to her treatment
regimen with subjective improvement. Oxygen therapy was
also initiated following deterioration in exercise capacity
(6MWD 473 m). Despite further subjective improvement,
repeated RHC showed worsening haemodynamics with an
increase in mean pulmonary arterial pressure, reduction in
cardiac index and worsening mixed venous oxygen saturation.
In May 2008, the patient was recommended for a double lung
transplant. In the period between May and December 2008
there was further deterioration in functional capacity and
oxygen saturation, requiring an increase in her furosemide
dose to 375 mg?day-1. Her exercise capacity continued to
decline (6MWD 347 m). Double lung transplantation was
performed on January 20, 2009. Histological analysis of
explanted lung tissue showed an atherosclerotic plaque in
the lower pulmonary artery, interstitial oedema, massive
alveolar congestion, iron-laden macrophages, and fibrous
thickening, obstruction and arterialisation of the septal and
pre-septal pulmonary veins (fig. 2). There was no apparent
capillary involvement.
Following transplantation, echocardiography showed normal-
isation of the patient’s heart shape and movement of the
interventricular septum. The patient is fine and without
symptoms 4 months after transplantation.
DISCUSSION
PVOD is one of the more malignant forms of pulmonary
hypertension, with an estimated 1-yr mortality of 72% [1].
Unlike PAH, which only affects the distal pulmonary arteries,
PVOD preferentially involves septal veins and pre-septal
venules. Despite this difference, patients with PVOD may
present with very similar clinical symptoms and haemo-
dynamic characteristics as patients with idiopathic PAH.
Therefore, differential diagnosis of PVOD can be challenging
and misdiagnosis is relatively common. Around 5–10% of
patients originally diagnosed with idiopathic PAH are subse-
quently found to have PVOD [2], and a recent study of patients
diagnosed with various forms of PAH who failed to respond to
therapy observed that 86% actually had PVOD [3].
Patients with PVOD may have a heterogeneous clinical
presentation; a high degree of clinical suspicion and appro-
priate diagnostic work-up are required for diagnosis. Although
a definitive diagnosis relies on histological examination of lung
biopsies, this procedure is particularly high risk in these
patients. However, a number of diagnostic tests can confirm
TABLE 1 Haemodynamic parameters on presentation and
following treatment with bosentan plus high
doses of furosemide
Presentation# Bosentan plus
furosemide"
Heart rate beats?min-1 120 110
Right atrial pressure mmHg 11 3
Pulmonary artery pressure
s/d/m mmHg
98/50/70 85/48/63
Pulmonary wedge pressure mmHg 10 8
Trans-pulmonary gradient mmHg 60 55
Blood pressure s/d/m mmHg 102/76/90 94/73/79
Cardiac output L?min1 2.5 4.0
Cardiac index L?min-1?m-2 1.4 2.4
PVR mmHg?L-1?min-1 24 13.8
SVR mmHg?L-1?min-1 31.6 19.0
PVR/SVR 0.8 0.7
Sa,O2 % 88 95
Sv,O2 % 39.1 60
s: systolic; d: diastolic; m: mean; PVR: pulmonary vascular resistance; SVR:
systemic vascular resistance; Sa,O2: arterial oxygen saturation; Sv,O2: mixed
venous oxygen saturation. #: oxygen, 6 L?min-1; ": breathing room air.
FIGURE 1. High-resolution computed tomography illustrating diffuse ground-
glass opacities with thickening interlobular septa.
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the diagnosis of PVOD without the requirement for invasive
techniques. Characteristic findings include centrilobular ground-
glass opacities, septal lines and mediastinal lymph node
enlargement on high-resolution computed tomography of the
chest, and the presence of haemosiderin-laden macrophages on
bronchoalveolar lavage [4, 5]. In addition, patients with PVOD
have lower arterial oxygen tension at rest, lower oxygen
saturation nadir during the 6-min walk test and lower diffusing
lung capacity of carbon monoxide/alveolar volume than those
with idiopathic PAH [4, 5].
PVOD is notoriously unresponsive to medical therapy and there
are few treatment options other than lung transplantation for
these patients. Clinical similarities suggest that PAH-specific
therapies may be of use in these patients, but data are limited. A
major concern with such treatment in PVOD is the development
of pulmonary oedema, which can be potentially fatal.
Pulmonary oedema has been reported with all classes of PAH-
specific therapies including prostacyclins, calcium channel
blockers, endothelin receptor antagonists and phosphodiester-
ase type-5 inhibitors, and may be most common with
epoprostenol and calcium channel blockers [1, 4, 5]. Despite
this, clinical improvement or stabilisation has been reported in a
small number of patients treated with continuous intravenous
prostacyclin [1, 6], oral sildenafil [7] and oral bosentan [8].
Recently, cautious use of continuous i.v. epoprostenol for 3–
4 months was found to improve clinical and haemodynamic
parameters in 12 patients with PVOD, suggesting that such
therapy may be a useful bridge to lung transplantation [9].
Treatment of our patient with bosentan, in combination with
high doses of furosemide to reduce lymphatic and venous
congestion, may have contributed to improvements in her
clinical status and may have slowed disease progression.
Despite treatment, progressive deterioration continued, requir-
ing eventual lung transplantation. Cautious use of specific drug
treatments for PAH, while not curative, may be useful as a
bridging therapy to lung transplantation in patients with PVOD.
In conclusion, PVOD is a rare and severe form of pulmonary
hypertension that presents a number of diagnostic challenges.
Patients with PVOD may have a heterogeneous clinical
presentation, requiring a high degree of clinical suspicion
and robust diagnostic work-up. Misdiagnosis is relatively
common. Accurate diagnosis is essential for appropriate
management, especially since some PAH-specific therapies
may be harmful in patients with PVOD. Although lung
transplantation is the treatment of choice for patients with
PVOD, the use of specific therapies for PAH in addition to high
doses of diuretics may be helpful in some patients, and merits
further evaluation.
a)
c)
b)
FIGURE 2. Histopathology of the explanted lung tissue. a) Interstitial
oedema of the lung parenchyma and massive alveolar congestion. b)
Transversal and c) longitudinal sections of a lung small vein showing
fibrotic occlusive lesions, wall thickening and muscularisation.
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